Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow BDTX
Black Diamond Therapeutics, Inc. (BDTX) P/E ratio
Black Diamond Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 32.4× (June 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 6.2× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 19.4× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| COYA Coya Therapeutics, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| CBUS Cibus, Inc. compare | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| BDTX Black Diamond Therapeutics, Inc. | n/m |
| UNCY Unicycive Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)